Purpose: This study aimed to explore the diagnostic performance of single photon emission computed tomography / computerized tomography (SPECT/CT) using a new radiotracer 99m Tc-RGD-BBN for breast malignant tumor compared with 99m Tc-3P4-RGD 2. Methods: 6 female patients with breastmalignant tumors diagnosed by fine needle aspiration cytology biopsy (FNAB) who were scheduled to undergo surgery were included in the study. 99m Tc-3P4-RGD 2 and 99m Tc-RGD-BBN were performed with single photon emission computed tomography (SPECT) at 1 hour after intravenous injection of 299 ± 30 MBq and 293 ± 32 MBq of radiotracers respectively at separate day. The results were evaluated by the Tumor to non-Tumor ratios (T/NT). 99m Tc-RGD-BBN and 99m Tc-3P4-RGD 2 SPECT/CT images were interpreted independently by 3 experienced nuclear medicine physicians using a 3-point scale system. All of the samples were analyzed immunohistochemically to evaluate the integrin αvβ3 and gastrin-releasing peptide receptor (GRPR) expression. The safety, biodistribution and radiation dosimetry of 99m Tc-RGD-BBN were also evaluated in the healthy volunteers. Results: No serious adverse events were reported in any of the patients during the study. The effective radiation dose entirely conformed to the relevant standards. A total of 6 palpable malignant lesions were detected using 99m Tc-RGD-BBN SPECT/CT with clear uptake. All malignant lesions were also detected using 99m Tc-3P4-RGD 2 SPECT/CT. The results showed that five malignant lesions were with clear uptake and the other one with barely an uptake. 4 malignant cases were found with both αvβ3 and GRPR expression, 1 case with only GRPR positive expression (integrin αvβ3 negative) and 1 case with only integrin αvβ3 positive expression (GRPR negative). Conclusion: 99m Tc-RGD-BBN is a safe agent for detecting breast cancer. 99m Tc-RGD-BBN may have the potential to make up for the deficiency of 99m Tc-3P4-RGD 2 in the detection of breast cancer with only GRPR positive expression (integrin α v β 3 negative). The preliminary application of 99m Tc-RGD-BBN has demonstrated its powerful potential in breast cancer diagnosis and therapy.
CITATION STYLE
Q., C., Q., M., M., C., B., C., Q., W., B., J., … S., G. (2015). An exploratory study on 99m Tc-RGD-BBN peptide scintimammography in the assessment of breast malignant lesions compared to 99m Tc-3P4-RGD2. PLoS ONE, 10(4). Retrieved from http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L603666445
Mendeley helps you to discover research relevant for your work.